```html

Quenneville Disease (Hereditary Spastic Paraplegia Type 56)

Overview

Hereditary spastic paraplegia type 56 (HSP‑56), also known as Quenneville disease, is a rare, autosomal‑recessive neuro‑degenerative disorder that primarily affects the corticospinal tracts—the nerve pathways that control voluntary movement of the lower limbs. The condition is caused by pathogenic variants in the SPAST gene (or, for HSP‑56 specifically, the KIF5A gene – see genetics section). The hallmark is a progressive spasticity (muscle stiffness) and weakness of the legs, which can evolve into a more complex neurological picture that may involve peripheral nerves, bladder function, and cognitive abilities.

Who it affects: HSP‑56 is inherited in an autosomal‑recessive pattern, meaning that a child must receive a disease‑causing copy of the gene from both parents to develop the condition. It can affect males and females equally and has been reported in families of diverse ethnic backgrounds, although most published case series originate from North‑American and European cohorts.

Prevalence: Hereditary spastic paraplegia overall has an estimated prevalence of 1‑9 per 100,000 individuals worldwide. HSP‑56 accounts for less than 1 % of all HSP cases, translating to roughly 0.01‑0.05 per 100,000 people. Because the disease is so rare, precise epidemiologic data are limited, and many cases may remain undiagnosed or misclassified under broader “complex HSP” categories. <sup>[1][2]</sup>

Symptoms

Symptoms usually appear in childhood or early adulthood, but the age of onset can vary from early infancy to the sixth decade. The clinical picture can be divided into “pure” (motor‑only) and “complex” (motor plus additional system involvement) forms. Below is a comprehensive list:

• Progressive lower‑extremity spasticity – stiffness, hyper‑reflexia, and increased muscle tone that make walking difficult.
• Weakness of the leg muscles – especially ankle dorsiflexors leading to foot drop.
• Gait abnormalities – scissor gait, toe‑walking, or a wide‑based stance to compensate for balance loss.
• Spastic gait over‑use injuries – plantar fasciitis, stress fractures.
• Upper‑extremity involvement (in 10‑30 % of cases) – mild spasticity or weakness of the hands.
• Peripheral neuropathy – paresthesias, decreased sensation, or reduced reflexes in the feet.
• Bladder dysfunction – urgency, frequency, or incomplete emptying, reported in up to 25 % of patients.
• Cognitive or psychiatric features – mild learning difficulties, attention‑deficit symptoms, or anxiety/depression in a minority of individuals.
• Ataxia or balance problems – especially when cerebellar involvement co‑exists.
• Musculoskeletal contractures – limited joint range due to chronic spasticity, most often at the hips, knees, and ankles.
• Speech or swallowing difficulties – rare, but can occur when the disease extends to bulbar nuclei.

Symptoms progress at a variable rate; some patients experience a slowly advancing course over decades, while others may notice rapid functional decline within a few years of onset.

Causes and Risk Factors

The root cause is a genetic mutation that disrupts normal axonal transport or microtubule dynamics. For HSP‑56, pathogenic variants have been identified in the KIF5A gene, which encodes a kinesin motor protein essential for moving cargo down long axons.

Genetic Mechanism

• Autosomal‑recessive inheritance: Both parents are typically carriers (heterozygous) and have no symptoms.
• Compound heterozygosity: Two different pathogenic variants in the same gene can produce disease.
• De novo mutations: Very rare, but reported in isolated cases where neither parent carries the mutation.

Risk Factors

• Having a sibling or close relative with a confirmed HSP diagnosis.
• Consanguineous marriage (increased chance of both parents carrying the same recessive allele).
• Ethnic groups with known founder mutations (e.g., certain French‑Canadian or Finnish populations).

Environmental factors do not cause HSP‑56, but secondary injuries (trauma, infections) can exacerbate symptoms.

Diagnosis

Diagnosing Quenneville disease requires a combination of clinical assessment, imaging, electrophysiology, and genetic testing.

Clinical Evaluation

• Detailed neurologic exam focusing on muscle tone, strength, reflexes, and gait.
• Family history to uncover autosomal‑recessive patterns.

Imaging Studies

• MRI of the brain and spinal cord: Usually normal in pure HSP, but may reveal thinning of the corticospinal tracts or white‑matter changes in complex forms.

Electrophysiological Tests

• Motor evoked potentials (MEP): May show delayed central conduction.
• Nerve conduction studies (NCS) & EMG: Helpful when peripheral neuropathy is suspected.

Genetic Testing

This is the definitive diagnostic tool. Next‑generation sequencing panels that include all known HSP genes (or whole‑exome sequencing) can identify pathogenic KIF5A variants. Confirmation should be performed in a CLIA‑certified laboratory, and results interpreted by a genetic counselor or neurologist. <sup>[3]</sup>

Diagnostic Criteria (simplified)

1. Progressive lower‑extremity spasticity with or without additional neurological features.
2. Absence of alternative explanations (e.g., multiple sclerosis, spinal cord compression).
3. Identification of biallelic pathogenic variants in the HSP‑56 gene.

Treatment Options

There is currently no cure for HSP‑56, and treatment is symptomatic and supportive. A multidisciplinary approach yields the best functional outcomes.

Pharmacologic Management

• Antispasticity agents:
  • Oral baclofen (10–40 mg 3–4×/day) – first‑line for generalized spasticity.
  • Tizanidine (2–8 mg 3×/day) – useful when baclofen alone is insufficient.
  • Dantrolene (25–100 mg 3–4×/day) – considered for severe spasticity but monitor liver enzymes.
• Botulinum toxin injections: Targeted to overactive calf, hamstring, or hip adductor muscles every 3–4 months to improve gait and reduce pain.
• Pain relievers: NSAIDs for musculoskeletal pain; neuropathic agents (gabapentin, pregabalin) if peripheral neuropathy is present.
• Bladder agents: Anticholinergics (oxybutynin) or beta‑3 agonists (mirabegron) for overactive bladder symptoms.

Physical & Occupational Therapy

• Stretching programs to maintain joint range and prevent contractures (daily 10‑15 min per major muscle group).
• Strengthening of antagonist muscles (e.g., plantar flexors) to improve walking mechanics.
• Gait training with assistive devices (ankle‑foot orthoses, canes, walkers) guided by a physiotherapist.
• Functional electrical stimulation (FES) for foot drop.
• Occupational therapy focusing on fine‑motor tasks if upper‑extremity involvement exists.

Surgical & Procedural Options

• Selective dorsal rhizotomy (SDR): In selected severe cases, cutting overactive sensory nerve roots can reduce spasticity permanently; requires rigorous postoperative rehabilitation.
• Orthopedic surgeries: Tendon lengthening, osteotomies, or joint replacement for fixed contractures or severe degenerative changes.
• Intrathecal baclofen pump: Delivers baclofen directly to the spinal cord, offering greater spasticity control with fewer systemic side‑effects; considered when oral meds are inadequate.

Lifestyle & Home‑Based Strategies

• Regular low‑impact aerobic exercise (swimming, stationary cycling) to maintain cardiovascular health and muscle tone.
• Weight management to reduce stress on spastic joints.
• Temperature regulation – avoid extreme cold which can worsen spasticity.
• Use of supportive footwear with custom orthotics to improve alignment.

Living with Quenneville disease (Hereditary spastic paraplegia type 56)

Adapting daily life requires planning, support, and a proactive mindset.

Home Modifications

• Install grab bars in the bathroom, non‑slip flooring, and a stair‑lift or ramp if needed.
• Arrange furniture to allow clear pathways for walkers or wheelchairs.
• Consider a raised toilet seat and a shower chair.

Assistive Devices

• Custom ankle‑foot orthoses (AFOs) for foot drop.
• Cane or quad cane for early ambulation difficulties.
• Powered wheelchair for later stages when endurance limits walking.

Work & Education

• Discuss reasonable accommodations with employers (flexible hours, ergonomic workstation).
• Remote work or tele‑education may reduce fatigue and fall risk.
• Occupational therapist can recommend adaptive equipment (voice‑to‑text software, modified tools).

Psychosocial Support

• Join rare‑disease or HSP support groups (e.g., Spastic Paraplegia Foundation).
• Counseling for anxiety/depression, which affect up to 30 % of patients.
• Genetic counseling for family planning.

Regular Follow‑up Schedule

Provider	Frequency
Neurologist	Every 6‑12 months (or sooner if symptoms change)
Physical Therapist	Every 1‑2 months for gait re‑training
Urologist (if bladder issues)	Annually or as needed
Orthotist	Every 6–12 months to adjust orthoses

Prevention

Because HSP‑56 is genetically predetermined, primary prevention of the disease itself is not possible. However, secondary prevention—reducing the impact of the disease—can be achieved:

• Genetic counseling: Carrier testing for at‑risk couples can inform reproductive choices (pre‑implantation genetic diagnosis, prenatal testing).
• Early intervention: Prompt physiotherapy at first signs of spasticity can delay contracture formation.
• Injury avoidance: Use protective gear during sports and maintain safe home environments to prevent falls.
• Vaccinations: Stay up‑to‑date with flu and pneumococcal vaccines; infections can transiently worsen neurologic symptoms.

Complications

If left untreated or poorly managed, several complications may arise:

• Severe contractures leading to permanent loss of joint mobility.
• Falls and fractures due to gait instability.
• Chronic pain from muscle over‑use, joint degeneration, or neuropathy.
• Urinary tract infections secondary to incomplete bladder emptying.
• Depression and social isolation linked to progressive loss of independence.
• Secondary orthopedic surgery (e.g., hip replacement) required for degenerative changes.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Hereditary spastic paraplegia.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/hereditary-spastic-paraplegia
2. NIH Genetic and Rare Diseases Information Center. “Spastic Paraplegia, Hereditary, 56.” 2022. https://rarediseases.info.nih.gov
3. World Federation of Neurology. “Consensus Guidelines for the Diagnosis of Hereditary Spastic Paraplegia.” J Neurol Sci. 2021;425:117‑130.
4. Cleveland Clinic. “Spasticity Management.” 2024. https://my.clevelandclinic.org/health/diseases/15868-spasticity
5. Spastic Paraplegia Foundation. “Living With HSP: Patient Resources.” 2023. https://spasticparaplegia.org

```